Loading…

Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India

Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment...

Full description

Saved in:
Bibliographic Details
Published in:The National medical journal of India 2020-09, Vol.33 (5), p.271-275
Main Authors: Pathy, Sushmita, Venkatesulu, Bhanu, Mallick, Supriya, Deo, Suryanarayana, Mohanti, Bidhu
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 275
container_issue 5
container_start_page 271
container_title The National medical journal of India
container_volume 33
creator Pathy, Sushmita
Venkatesulu, Bhanu
Mallick, Supriya
Deo, Suryanarayana
Mohanti, Bidhu
description Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment of lymph nodes in the neck is debatable. We reviewed the utility of RT for lymph nodes in the neck in patients with malignant tumours of the eyelid. Methods. We reviewed medical records of all patients with tumours of the eyelid treated at our centre from July 2006 to December 2014 for their demographic, clinical profile, treatment details and outcome. Results. The records of 37 patients were included for analysis, of these 34 underwent surgery and 21 received adjuvant RT. Their median age was 60 (range 30-85) years. Sebaceous cell carcinoma was the most common (50.4%). The median disease-free survival (DFS) was 35 months (95% CI 17.9-52.0). The 1- and 3-year DFS were 82.7% and 45%, respectively. Univariate analysis showed a superior outcome with early stage (T1) tumours (p=0.01), RT dose of ≥60 Gy and those underwent lymph node dissection (p=0.03). The presence of high-risk factors including close or positive margin had an inferior outcome with a trend towards statistical significance (p=0.06). Conclusion. We found a favourable outcome with early T stage, RT dose of ≥60 Gy and lymph node dissection. High-risk histopathological features including close margins and positive lymph nodes merit adjuvant RT including regional lymph nodes.
doi_str_mv 10.4103/0970-258X.317464
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2548416594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A666699239</galeid><sourcerecordid>A666699239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-d7719863fd3c65428f1e33f1c756533f2e65c651e5b2f5dcff6576841d8cf9d23</originalsourceid><addsrcrecordid>eNptks9vFCEUxyfGJtbWu0cSE-NltgMMzIy3tWlrkyZeNPFGEB5dtgxsgem6_71MVu2uEQ68PD7fx4_vq6q3uFm0uKEXzdA1NWH99wXFXcvbF9Xp39TLg_hV9TqlddNwihk-rR6Xej09SZ9RlNrKbINHeQVRbnbIhIhG6ey9n_fzNIYpJhTMDCDYgbP6I7r6uYFowStAJoYRSZQhZivjDilZshEp8DkCsh7d-nLEeXVipEvw5vd6Vn27vvp6-bm--3Jze7m8q1WL21zrrsNDz6nRVHHWkt5goNRg1THOSkCAs7KBgf0ghmllDGcd71use2UGTehZ9WFfdxPD4wQpi9EmBc5JD2FKgrC20JwNbUHf_YOuy1N9ud1McUZ6MjTP1L10IKw3IUep5qJiycsYBkKHQi3-Q5WpYbQqeDC25I8E7w8EK5Aur1Jw02xFOgabPahiSCmCEZtox_LRAjdi7gExmyxmk8W-B4rk016yDa7Ykh7ctIUoRtAPPmyPdPWBTpAOiz-NQX8BZ_S3xQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2546528290</pqid></control><display><type>article</type><title>Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India</title><source>Alma/SFX Local Collection</source><creator>Pathy, Sushmita ; Venkatesulu, Bhanu ; Mallick, Supriya ; Deo, Suryanarayana ; Mohanti, Bidhu</creator><creatorcontrib>Pathy, Sushmita ; Venkatesulu, Bhanu ; Mallick, Supriya ; Deo, Suryanarayana ; Mohanti, Bidhu</creatorcontrib><description>Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment of lymph nodes in the neck is debatable. We reviewed the utility of RT for lymph nodes in the neck in patients with malignant tumours of the eyelid. Methods. We reviewed medical records of all patients with tumours of the eyelid treated at our centre from July 2006 to December 2014 for their demographic, clinical profile, treatment details and outcome. Results. The records of 37 patients were included for analysis, of these 34 underwent surgery and 21 received adjuvant RT. Their median age was 60 (range 30-85) years. Sebaceous cell carcinoma was the most common (50.4%). The median disease-free survival (DFS) was 35 months (95% CI 17.9-52.0). The 1- and 3-year DFS were 82.7% and 45%, respectively. Univariate analysis showed a superior outcome with early stage (T1) tumours (p=0.01), RT dose of ≥60 Gy and those underwent lymph node dissection (p=0.03). The presence of high-risk factors including close or positive margin had an inferior outcome with a trend towards statistical significance (p=0.06). Conclusion. We found a favourable outcome with early T stage, RT dose of ≥60 Gy and lymph node dissection. High-risk histopathological features including close margins and positive lymph nodes merit adjuvant RT including regional lymph nodes.</description><identifier>ISSN: 0970-258X</identifier><identifier>EISSN: 0970-258X</identifier><identifier>DOI: 10.4103/0970-258X.317464</identifier><language>eng</language><publisher>New Delhi: Wolters Kluwer India Pvt. Ltd</publisher><subject>Cancer ; Care and treatment ; Lymphatic system ; Medical records ; Radiation ; Radiation therapy ; Radiotherapy ; Tumors</subject><ispartof>The National medical journal of India, 2020-09, Vol.33 (5), p.271-275</ispartof><rights>COPYRIGHT 2020 Medknow Publications and Media Pvt. Ltd.</rights><rights>2020. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Pathy, Sushmita</creatorcontrib><creatorcontrib>Venkatesulu, Bhanu</creatorcontrib><creatorcontrib>Mallick, Supriya</creatorcontrib><creatorcontrib>Deo, Suryanarayana</creatorcontrib><creatorcontrib>Mohanti, Bidhu</creatorcontrib><title>Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India</title><title>The National medical journal of India</title><description>Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment of lymph nodes in the neck is debatable. We reviewed the utility of RT for lymph nodes in the neck in patients with malignant tumours of the eyelid. Methods. We reviewed medical records of all patients with tumours of the eyelid treated at our centre from July 2006 to December 2014 for their demographic, clinical profile, treatment details and outcome. Results. The records of 37 patients were included for analysis, of these 34 underwent surgery and 21 received adjuvant RT. Their median age was 60 (range 30-85) years. Sebaceous cell carcinoma was the most common (50.4%). The median disease-free survival (DFS) was 35 months (95% CI 17.9-52.0). The 1- and 3-year DFS were 82.7% and 45%, respectively. Univariate analysis showed a superior outcome with early stage (T1) tumours (p=0.01), RT dose of ≥60 Gy and those underwent lymph node dissection (p=0.03). The presence of high-risk factors including close or positive margin had an inferior outcome with a trend towards statistical significance (p=0.06). Conclusion. We found a favourable outcome with early T stage, RT dose of ≥60 Gy and lymph node dissection. High-risk histopathological features including close margins and positive lymph nodes merit adjuvant RT including regional lymph nodes.</description><subject>Cancer</subject><subject>Care and treatment</subject><subject>Lymphatic system</subject><subject>Medical records</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Tumors</subject><issn>0970-258X</issn><issn>0970-258X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNptks9vFCEUxyfGJtbWu0cSE-NltgMMzIy3tWlrkyZeNPFGEB5dtgxsgem6_71MVu2uEQ68PD7fx4_vq6q3uFm0uKEXzdA1NWH99wXFXcvbF9Xp39TLg_hV9TqlddNwihk-rR6Xej09SZ9RlNrKbINHeQVRbnbIhIhG6ey9n_fzNIYpJhTMDCDYgbP6I7r6uYFowStAJoYRSZQhZivjDilZshEp8DkCsh7d-nLEeXVipEvw5vd6Vn27vvp6-bm--3Jze7m8q1WL21zrrsNDz6nRVHHWkt5goNRg1THOSkCAs7KBgf0ghmllDGcd71use2UGTehZ9WFfdxPD4wQpi9EmBc5JD2FKgrC20JwNbUHf_YOuy1N9ud1McUZ6MjTP1L10IKw3IUep5qJiycsYBkKHQi3-Q5WpYbQqeDC25I8E7w8EK5Aur1Jw02xFOgabPahiSCmCEZtox_LRAjdi7gExmyxmk8W-B4rk016yDa7Ykh7ctIUoRtAPPmyPdPWBTpAOiz-NQX8BZ_S3xQ</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Pathy, Sushmita</creator><creator>Venkatesulu, Bhanu</creator><creator>Mallick, Supriya</creator><creator>Deo, Suryanarayana</creator><creator>Mohanti, Bidhu</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Scientific Scholar</general><scope>AAYXX</scope><scope>CITATION</scope><scope>04Q</scope><scope>04T</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200901</creationdate><title>Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India</title><author>Pathy, Sushmita ; Venkatesulu, Bhanu ; Mallick, Supriya ; Deo, Suryanarayana ; Mohanti, Bidhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-d7719863fd3c65428f1e33f1c756533f2e65c651e5b2f5dcff6576841d8cf9d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer</topic><topic>Care and treatment</topic><topic>Lymphatic system</topic><topic>Medical records</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pathy, Sushmita</creatorcontrib><creatorcontrib>Venkatesulu, Bhanu</creatorcontrib><creatorcontrib>Mallick, Supriya</creatorcontrib><creatorcontrib>Deo, Suryanarayana</creatorcontrib><creatorcontrib>Mohanti, Bidhu</creatorcontrib><collection>CrossRef</collection><collection>India Database</collection><collection>India Database: Health &amp; Medicine</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The National medical journal of India</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pathy, Sushmita</au><au>Venkatesulu, Bhanu</au><au>Mallick, Supriya</au><au>Deo, Suryanarayana</au><au>Mohanti, Bidhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India</atitle><jtitle>The National medical journal of India</jtitle><date>2020-09-01</date><risdate>2020</risdate><volume>33</volume><issue>5</issue><spage>271</spage><epage>275</epage><pages>271-275</pages><issn>0970-258X</issn><eissn>0970-258X</eissn><abstract>Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment of lymph nodes in the neck is debatable. We reviewed the utility of RT for lymph nodes in the neck in patients with malignant tumours of the eyelid. Methods. We reviewed medical records of all patients with tumours of the eyelid treated at our centre from July 2006 to December 2014 for their demographic, clinical profile, treatment details and outcome. Results. The records of 37 patients were included for analysis, of these 34 underwent surgery and 21 received adjuvant RT. Their median age was 60 (range 30-85) years. Sebaceous cell carcinoma was the most common (50.4%). The median disease-free survival (DFS) was 35 months (95% CI 17.9-52.0). The 1- and 3-year DFS were 82.7% and 45%, respectively. Univariate analysis showed a superior outcome with early stage (T1) tumours (p=0.01), RT dose of ≥60 Gy and those underwent lymph node dissection (p=0.03). The presence of high-risk factors including close or positive margin had an inferior outcome with a trend towards statistical significance (p=0.06). Conclusion. We found a favourable outcome with early T stage, RT dose of ≥60 Gy and lymph node dissection. High-risk histopathological features including close margins and positive lymph nodes merit adjuvant RT including regional lymph nodes.</abstract><cop>New Delhi</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/0970-258X.317464</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0970-258X
ispartof The National medical journal of India, 2020-09, Vol.33 (5), p.271-275
issn 0970-258X
0970-258X
language eng
recordid cdi_proquest_miscellaneous_2548416594
source Alma/SFX Local Collection
subjects Cancer
Care and treatment
Lymphatic system
Medical records
Radiation
Radiation therapy
Radiotherapy
Tumors
title Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A24%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20radiation%20therapy%20for%20malignant%20tumours%20of%20the%20eyelid:%20Experience%20from%20a%20tertiary%20cancer%20centre%20in%20India&rft.jtitle=The%20National%20medical%20journal%20of%20India&rft.au=Pathy,%20Sushmita&rft.date=2020-09-01&rft.volume=33&rft.issue=5&rft.spage=271&rft.epage=275&rft.pages=271-275&rft.issn=0970-258X&rft.eissn=0970-258X&rft_id=info:doi/10.4103/0970-258X.317464&rft_dat=%3Cgale_proqu%3EA666699239%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c414t-d7719863fd3c65428f1e33f1c756533f2e65c651e5b2f5dcff6576841d8cf9d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2546528290&rft_id=info:pmid/&rft_galeid=A666699239&rfr_iscdi=true